Zobrazeno 1 - 10
of 100
pro vyhledávání: '"NICOLA SGHERZA"'
Autor:
Pellegrino Musto, Nicola Sgherza
Publikováno v:
Mediterranean Journal of Hematology and Infectious Diseases, Vol 16, Iss 1 (2024)
x
Externí odkaz:
https://doaj.org/article/07d091fd089345989a68d5b044bdad7c
Publikováno v:
Mediterranean Journal of Hematology and Infectious Diseases, Vol 16, Iss 1 (2024)
Externí odkaz:
https://doaj.org/article/1d3a3524b66b4afeb4a075a0dfd167c7
Autor:
Massimo Gentile, Ernesto Vigna, Salvatore Palmieri, Monica Galli, Daniele Derudas, Roberto Mina, Roberta Della Pepa, Renato Zambello, Enrica Antonia Martino, Antonella Bruzzese, Silvia Mangiacavalli, Elena Zamagni, Catello Califano, Maurizio Musso, Concetta Conticello, Claudio Cerchione, Giuseppe Mele, Nicola Di Renzo, Massimo Offidani, Giuseppe Tarantini, Gloria Margiotta Casaluci, Angela Rago, Roberto Ria, Giuseppina Uccello, Gregorio Barilà, Gaetano Palumbo, Alessandra Pompa, Donatella Vincelli, Marino Brunori, Fabrizio Accardi, Valeria Amico, Angela Amendola, Raffaele Fontana, Velia Bongarzoni, Bernardo Rossini, Emilia Cotzia, Alessandro Gozzetti, Rita Rizzi, Nicola Sgherza, Eleonora Ferretti, Giuseppe Bertuglia, Davide Nappi, Maria Teresa Petrucci, Francesco Di Raimondo, Antonino Neri, Fortunato Morabito, Pellegrino Musto
Publikováno v:
Haematologica, Vol 109, Iss 1 (2023)
In the ELOQUENT-3 trial, the combination of elotuzumab, pomalidomide and dexamethasone (EloPd) proved to have a superior clinical benefit over pomalidomide and dexamethasone with a manageable toxicity profile, leading to its approval for the treatmen
Externí odkaz:
https://doaj.org/article/73f1dbd9f0594c46b0da5f764f3377db
Autor:
NICOLA SGHERZA, Paola Curci, Rita Rizzi, Angela Maria Vittoria Larocca, Luigi Vimercati, Silvio Tafuri, Maria Chironna, Pellegrino Musto
Publikováno v:
Mediterranean Journal of Hematology and Infectious Diseases, Vol 15, Iss 1 (2023)
Not Applicable.
Externí odkaz:
https://doaj.org/article/d4a7dded78e748cebffe57d2395a0ba1
Autor:
Nicola Sgherza, Daniela Di Gennaro, Paola Curci, Rita Rizzi, Daniela Roccotelli, Maria Croce, Martina Avantaggiato, Loredana Ruga, Vanda Strafella, Angelantonio Vitucci, Antonio Palma, Antonella V. Russo Rossi, Teresa Troiano, Angela M. V. Larocca, Maria Chironna, Silvio Tafuri, Francesco Albano, Pellegrino Musto
Publikováno v:
HemaSphere, Vol 6, Iss 12, p e800 (2022)
Externí odkaz:
https://doaj.org/article/2a6262732a324e758a9662a8e4cd2c92
Autor:
Nicola Sgherza, Paola Curci, Rita Rizzi, Immacolata Attolico, Daniela Loconsole, Anna Mestice, Maria Chironna, Pellegrino Musto
Publikováno v:
Blood Cancer Journal, Vol 11, Iss 12, Pp 1-3 (2021)
Externí odkaz:
https://doaj.org/article/73a973c7a7da4807b877e81b047b0fb9
Autor:
NICOLA SGHERZA, Stefania Zucano, Angelantonio Vitucci, Antonio Palma, Francesco Tarantini, Daniela Campanale, Luigi Vimercati, Angela Maria Vittoria Larocca, Domenico Visceglie, Amalia Acquafredda, Angelo Ostuni, Daniela Di Gennaro, Carmen Vitucci, Silvio Tafuri, Pellegrino Musto
Publikováno v:
Mediterranean Journal of Hematology and Infectious Diseases, Vol 14, Iss 1 (2022)
Externí odkaz:
https://doaj.org/article/d24fa06fb0994911b30c7936a8fccfbf
Autor:
Anna Sicuranza, Ilaria Ferrigno, Elisabetta Abruzzese, Alessandra Iurlo, Sara Galimberti, Antonella Gozzini, Luigiana Luciano, Fabio Stagno, Antonella Russo Rossi, Nicola Sgherza, Daniele Cattaneo, Corrado Zuanelli Brambilla, Cristina Marzano, Carmen Fava, Olga Mulas, Emanuele Cencini, Adele Santoni, Vincenzo Sammartano, Alessandro Gozzetti, Luca Puccetti, Monica Bocchia
Publikováno v:
Frontiers in Oncology, Vol 12 (2022)
Tyrosine kinase inhibitors (TKI) may offer a normal life expectancy to Chronic Myeloid Leukemia (CML) patients. However, a higher than expected incidence of arterial occlusive events (AOEs) was observed during treatment with nilotinib. We previously
Externí odkaz:
https://doaj.org/article/5ddf4f9f79054a4e8cbdd98e58692599
Autor:
Nicola Sgherza, Paola Curci, Rita Rizzi, Vanda Strafella, Daniela Di Gennaro, Angelantonio Vitucci, Antonio Palma, Antonella Vita Russo Rossi, Francesco Albano, Pasquale Stefanizzi, Silvio Tafuri, Pellegrino Musto
Publikováno v:
Haematologica, Vol 107, Iss 2 (2021)
Externí odkaz:
https://doaj.org/article/dac746c95bdc477f89a31fd9936f763f
Publikováno v:
Frontiers in Oncology, Vol 11 (2021)
Although the survival rate of patients with multiple myeloma has significantly improved in the last years thanks to the introduction of various classes of new drugs, such as proteasome inhibitors, immunomodulatory agents, and monoclonal antibodies, t
Externí odkaz:
https://doaj.org/article/9bd5a7ee5e4642c8800edf981c2f7798